Drug insight: Clopidogrel nonresponsiveness.


Journal Article (Review)

Platelet reactivity to agonists and subsequent activation are important factors that affect the development of atherothrombosis and resultant ischemic events. Pharmacologic intervention with clopidogrel and aspirin during acute coronary syndromes and percutaneous coronary intervention is considered the gold standard for attenuating platelet activation and aggregation. Despite significant benefits reported with dual antiplatelet treatment in major clinical trials, the occurrence of adverse ischemic events, including stent thrombosis, remains a serious clinical problem. Nonresponsiveness, also called resistance, to current clopidogrel regimens might play a part in the occurrence of ischemic events. Various mechanisms have been implicated in nonresponsiveness to clopidogrel, including variability in intestinal absorption and hepatic conversion to the active metabolite, drug-drug interactions and receptor polymorphisms. Increased loading and maintenance doses and the use of new and more-potent P2Y12-receptor blockers might overcome the phenomenon of clopidogrel nonresponsiveness. The aim of this article is to provide a comprehensive and current review of clopidogrel response variability and nonresponsiveness.

Full Text

Duke Authors

Cited Authors

  • Gurbel, PA; Tantry, US

Published Date

  • July 2006

Published In

Volume / Issue

  • 3 / 7

Start / End Page

  • 387 - 395

PubMed ID

  • 16810174

Pubmed Central ID

  • 16810174

International Standard Serial Number (ISSN)

  • 1743-4297

Digital Object Identifier (DOI)

  • 10.1038/ncpcardio0602


  • eng

Conference Location

  • England